Trump plans to ease access to psychedelics like psilocybin, ibogaine

The Trump administration is implementing executive directives to accelerate psychedelic medicine research and development. This policy shift, championed by Robert F. Kennedy Jr., aims to facilitate expanded clinical trials for substances including psilocybin and ibogaine. Federal agencies will receive guidance to support scientific investigation into these compounds' therapeutic potential for treating mental health conditions. The initiative represents a significant regulatory repositioning toward evidence-based research in psychopharmacology.